

Suppl. Table 3: Baseline characteristics of the study population.

	#R (n=162)	#NR (n=44)	^{\$}p value
OARSI Response			
Age (years)	61,47 (±8,50)	62,98 (±8,79)	0.301
Women (yes)	137 (84,6)	39 (88,6)	0.497
Caucasian race (yes)	159 (98,1)	44 (100)	0.363
Body mass index (kg/m ²)	30,76 (±5,97)	31,95 (±5,52)	0.186
Kellgren and Lawrence radiographic reading			0.348
Grade 2	101 (62,3)	24 (54,5)	
Grade 3	61 (37,7)	20 (45,5)	
WOMAC score (at inclusion)			
Pain scale	371,69 (±40,30)	362,32 (±47,35)	0.105
Stiffness scale	128,57 (±33,87)	123,59 (±33,63)	0.454
Function scale	1110,88 (±241,76)	1094,07 (±266,44)	0.582
Huskisson's visual analogue scale (pain intensity)	71,44 (±15,60)	72,48 (±16,19)	0.633
Joint swelling (yes)	20 (12,3)	5 (11,4)	0.86
Joint effusion (yes)	9 (5,6)	5 (11,4)	0.175
Patient's global assessment of disease activity	69,72 (±16,77)	64,27 (±17,70)	0.046
Investigator's global assessment of disease activity	62,79 (±14,50)	63,64 (±14,64)	0.681
EuroQoL-5D (health-related quality of life)			
Mobility	1,78 (±0,41)	1,86 (±0,35)	0.242
Self-care	1,41 (±0,49)	1,39 (±0,54)	0.832
Usual activities	1,77 (±0,44)	1,82 (±0,39)	0.455
Pain/discomfort	2,21 (±0,41)	2,34 (±0,48)	0.071
Anxiety/depression	1,67 (±0,58)	1,7 (±0,46)	0.571
Visual analogue scale	55,21 (±20,06)	51,41 (±22,82)	0.317
Eosinophils (blood)	3,01 (±1,81)	2,26 (±1,32)	0.017
Hemoglobin (blood)	8,78 (±0,69)	8,45 (±0,69)	0.013
Metabolic disorder previous (yes)	46 (28,4)	8 (18,2)	0.172

[#]Data are mean ± SD (quantitative variables) or n (%) (qualitative variables) in responders (R) and non-responders (NR) to CS+GH treatment.

^{\$}p values were calculated by Mann-Whitney *U* (quantitative variables) or Pearson Chi-Square tests (qualitative variables).